JAMA Psychiatry June 2014 PMID 24740528

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Adriana Feder, Michael K Parides, James W Murrough, Andrew M Perez, Julia E Morgan, Shireen Saxena, Katherine Kirkwood, Marije Aan Het Rot, Kyle A B Lapidus, Le-Ben Wan, Dan Iosifescu, Dennis S Charney

Download social card

Mentions

Peak: 2 in May 2019

across 6 sources since Oct 2018

Extended reach

2,565

potential audience

Total likes

Video views

1,911

Mentions per month

Oct 2018 – Oct 2025

Where it's discussed

News30 articles
Facebook10 posts
Blogs6 articles
X / Twitter2 posts
YouTube2 videos
Reddit2 posts

AI synopsis

What people are saying

The discussions feature references to the rapid symptom relief provided by ketamine, with phrases like 'notable decrease within 24 hours', indicating high interest. Comments about its safety and potential as a treatment, along with hashtags like #PTSD and #Ketamine, show active engagement and a recognition of its moderate impact on future PTSD treatment approaches.

AgreementModerate agreement

Most discussions recognize the study as promising or relevant, reflecting a generally positive stance.

InterestHigh interest

The discussions show strong interest, with posts highlighting keywords like 'efficacy', 'treatment', and 'significant improvement'.

EngagementModerate engagement

Participants reference the methodology and implications, indicating some depth in their engagement.

ImpactModerate impact

While there is optimism about potential treatment benefits, the impact is seen as moderate due to calls for further research.

Abstract in brief

The study investigated whether a single intravenous dose of ketamine could quickly and safely reduce symptoms of chronic PTSD and depression, showing significant improvement compared to a placebo (midazolam).
Results revealed that ketamine led to a rapid, notable decrease in PTSD symptoms within 24 hours, and also helped lessen depressive symptoms, with patients generally tolerating the treatment well.
The findings suggest that ketamine may be a promising treatment option for chronic PTSD, but further research is needed to confirm its long-term safety and effectiveness.]

Read the full abstract